The TOWARD study confirms Actemra plus DMARDs significantly improves RA symptoms and clinical remission rates compared to traditional DMARDs alone. Additionally, Actemra shows rapid normalisation of inflammation markers and improved quality of life in patients with rheumatoid arthritis.
The new guidelines offer clear recommendations on diagnosis and management of cows' milk allergy (CMA), recommending only extensively hydrolysed and amino acid-based formulas. Alternative milks such as soy, sheep, and goat are not recommended due to risk of cross-reactivity.
New data demonstrates that MabThera effectively relieves RA symptoms and improves remission rates with subsequent courses of therapy. The safety profile remains consistent even after seven courses of treatment, providing confidence for physicians to make informed treatment decisions.
Repeat MabThera treatment improves physical and mental aspects of quality of life measures in RA patients, with significant improvements in disease symptoms and structure. The therapy also inhibits joint structural damage, providing evidence of radiographic progression inhibition.
A phase III study shows Actemra significantly reduces radiographic joint destruction and disease activity scores in patients with early aggressive rheumatoid arthritis. The treatment was generally well-tolerated, with a low incidence of adverse events.
MabThera demonstrates significant improvements in symptom parameters, including tender and swollen joint counts and fatigue, with higher response rates compared to methotrexate alone. The treatment was well-tolerated, with consistent safety profiles across the six-month analysis.